Arca
Skip to content
Tools
Tools

DNA terminase

Complex in Human cytomegalovirus (strain AD169) (HHV-5) (Human herpesvirus 5) that 1 drug acts on.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1
  • Genes: 3

Who is on it, and how far along

Every drug ChEMBL records acting on TRM1, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Letermovir

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        LetermovirApprovedMerck & Co. (MSD)Small moleculeInhibitorDNA terminase inhibitor27

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 8 in all, from ClinicalTrials.gov.
        Letermovir for R+ StudyLetermovirPhase 4Not yet recruitingUniversity of Wisconsin, MadisonJul 15, 2026
        A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell TransplantationLetermovirNot applicableNot yet recruitingYang DonglinJul 14, 2026
        Letermovir vs Valganciclovir in CMV R+ Kidney TransplantLetermovirPhase 4Not yet recruitingElisabeth KincaideMay 6, 2026
        Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.LetermovirPhase 4RecruitingWeiShiMay 6, 2026
        Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic LymphohistiocytosisLetermovirNot applicableRecruitingBeijing Children's HospitalMar 23, 2026
        Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis DurationLetermovir—Not yet recruitingInstitute of Hematology & Blood Diseases Hospital, ChinaMar 2, 2026
        VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study ProtocolLetermovir—Not yet recruitingUniversity of Rome Tor VergataDec 16, 2025
        Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant RecipientsLetermovirPhase 4RecruitingFirst Affiliated Hospital Xi'an Jiaotong UniversityDec 5, 2025

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3991482, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-22. ChEMBL and Open Targets

        Esc

        Type a name: a tool, a company, a drug or brand, a condition, a gene or a state. Identifiers like K231234, NCT05012345 or NDA 215866 open their record.

        Logos are each company's own site icon, matched by name through Wikidata, or logos provided by Logo.dev.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.